IRB #

STUDY00017685

Title

CA209-816 - Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC

Principal Investigator

Jeremy Cetnar

Study Purpose

The primary purpose of this study is to compare the combination of a drug called nivolumab and a drug called ipilimumab to chemotherapy. The study
doctors want to learn more about which therapy is more effective in treating NSCLC.

Medical Condition(s)

“Non-Small Cell Lung Cancer” and “Platinum-Doublet, Early Stage”

Eligibility Criteria

• Are 18 years of age or older
• Have confirmed diagnosis of operable early stage NSCLC
• Do not have brain metastases
• Do not have autoimmune disease
• Have not had prior chemotherapy or other cancer therapy

Age Range

18 - 150

Healthy Volunteers Needed

No

Duration of Participation

Up to 10 years

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Bristol-Myers Squibb Research and Development

Recruitment End

10/31/2027

Compensation Provided

No


Go Back